




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 471/14, A61K 31/435 // (C07D 471/14, 235:00, 221:00, 221:00)</b>		A1	(11) International Publication Number: <b>WO 98/42707</b>
			(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/EP98/01615		(74) Common Representative: BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE).	
(22) International Filing Date: 19 March 1998 (19.03.98)			
(30) Priority Data: 97104961.4 24 March 1997 (24.03.97) EP (34) Countries for which the regional or international application was filed: DE et al. 197 47 929.4 30 October 1997 (30.10.97) DE		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH [DE/DE]; Byk-Gulden-Strasse 2, D-78467 Konstanz (DE).			
(72) Inventors (for all designated States except CA US): SIMON, Wolfgang-Alexander; Schubertstrasse 17, D-78464 Kon- stanz (DE). POSTIUS, Stefan; Austrasse 4b, D-78467 Kon- stanz (DE). RIEDEL, Richard; Durlbach 7, D-88339 Bad Waldsee (DE).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(72) Inventors; and (75) Inventors/Applicants (for US only): SENN-BILFINGER, Jörg [DE/DE]; Säntisstrasse 7, D-78464 Konstanz (DE). GRUNDLER, Gerhard [DE/DE]; Meersburger Strasse 4, D-78464 Konstanz (DE).			

## (54) Title: TETRAHYDROPYRIDO COMPOUNDS

## (57) Abstract

Compounds of formula (I) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.



(I)

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Tetrahydropyrido compounds

### Field of application of the invention


The invention relates to novel compounds which are used in the pharmaceutical industry as active compounds for the production of medicaments.

### Known technical background

U.S. Patent 4,468,400 describes tricyclic imidazo[1,2-a]pyridines having various ring systems fused onto the imidazopyridine parent structure, which should be suitable for the treatment of peptic ulcer disorders.

### Description of the invention

The invention relates to compounds of the formula I



in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen or halogen, one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or 1-4C-alkylcarbonyloxy, or in which R4a and R4b together are O (oxygen),

one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or 1-4C-alkylcarbonyloxy, or in which R5a and R5b together are O (oxygen),

or in which

one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand is in each case hydrogen, and the other substituents in each case together form a methylenedioxy radical (-O-CH<sub>2</sub>-O-) or an ethylenedioxy radical (-O-CH<sub>2</sub>-CH<sub>2</sub>-O-),

where R4a, R4b, R5a and R5b are not simultaneously hydrogen,

R6 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or trifluoromethyl and

R7 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy, and their salts.

1-4C-alkyl represents straight-chain or branched alkyl radicals having 1 to 4 carbon atoms. Examples which may be mentioned are the butyl radical, isobutyl radical, sec-butyl radical, tert-butyl radical, propyl radical, isopropyl radical, ethyl radical and the methyl radical. The methyl radical is preferred.

Hydroxy-1-4C-alkyl represents abovementioned 1-4C-alkyl radicals which are substituted by a hydroxyl group. Examples which may be mentioned are the hydroxymethyl radical, the 2-hydroxyethyl radical and the 3-hydroxypropyl radical. The hydroxymethyl radical is preferred.

Halogen in the sense of the invention is bromine, chlorine or fluorine.

1-4C-alkoxy represents radicals which, in addition to the oxygen atom, contain a straight-chain or branched alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are the butoxy radical, isobutoxy radical, sec-butoxy radical, tert-butoxy radical, propoxy radical, isopropoxy radical and preferably the ethoxy radical and methoxy radical.

1-4C-alkoxy-1-4C-alkoxy represents one of the abovementioned 1-4C-alkoxy radicals which is substituted by a further 1-4C-alkoxy radical. Examples which may be mentioned are the radicals 2-(methoxy)ethoxy (CH<sub>3</sub>-O-CH<sub>2</sub>-CH<sub>2</sub>-O-) and 2-(ethoxy)ethoxy (CH<sub>3</sub>-CH<sub>2</sub>-O-CH<sub>2</sub>-CH<sub>2</sub>-O-).

1-4C-alkylcarbonyloxy represents a carbonyloxy group to which is bonded one of the abovementioned 1-4C-alkyl radicals. An example which may be mentioned is the acetoxy radical (CH<sub>3</sub>CO-O-).

1-4C-alkoxycarbonyl represents a carbonyl group to which is bonded one of the abovementioned 1-4C-alkoxy radicals. Examples which may be mentioned are the methoxycarbonyl radical (CH<sub>3</sub>O-C(O)-) and the ethoxycarbonyl radical (CH<sub>3</sub>CH<sub>2</sub>O-C(O)-).

1-4C-alkoxycarbonylamino represents an amino radical which is substituted by one of the abovementioned 1-4C-alkoxycarbonyl radicals. Examples which may be mentioned are the ethoxycarbonylamino radical and the methoxycarbonylamino radical.

1-4C-alkoxy-1-4C-alkoxycarbonyl represents a carbonyl group to which is bonded one of the abovementioned 1-4C-alkoxy-1-4C-alkoxy radicals. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonyl radical ( $\text{CH}_3\text{-O-CH}_2\text{CH}_2\text{-O-CO-}$ ) and the 2-(ethoxy)ethoxycarbonyl radical ( $\text{CH}_3\text{CH}_2\text{-O-CH}_2\text{CH}_2\text{-O-CO-}$ ).

1-4C-alkoxy-1-4C-alkoxycarbonylamino represents an amino radical which is substituted by one of the abovementioned 1-4C-alkoxy-1-4C-alkoxycarbonyl radicals. Examples which may be mentioned are the 2-(methoxy)ethoxycarbonylamino radical and the 2-(ethoxy)ethoxycarbonylamino radical.

Suitable salts of compounds of the formula I - depending on substitution - are especially all acid addition salts. Particular mention may be made of the pharmacologically tolerable salts of the inorganic and organic acids customarily used in pharmacy. Those suitable are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulfosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulfonic acid, methanesulfonic acid or 3-hydroxy-2-naphthoic acid, where the acids are employed in salt preparation - depending on whether a mono- or polybasic acid is concerned and depending on which salt is desired - in an equimolar quantitative ratio or one differing therefrom.

Pharmacologically intolerable salts which can be initially obtained as process products, for example in the preparation of the compounds according to the invention on an industrial scale, are converted into pharmacologically tolerable salts by processes known to the person skilled in the art.

According to expert's knowledge the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of formula I as well as all solvates and in particular all hydrates of the salts of the compounds of formula I.

The compounds of the formula I have three chiral centers. The invention relates to all eight conceivable stereoisomers in any desired mixing ratio with one another, including the pure enantiomers, which are a preferred subject of the invention.

If one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand together form a methylenedioxy radical or ethylenedioxy radical, the two substituents which form the methylenedioxy radical or ethylenedioxy radical are preferably cis to one another.

Compounds to be emphasized are those of the formula I, in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen,

one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy, or in which R4a and R4b together are O (oxygen),

one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy, or in which R5a and R5b together are O (oxygen),


where R4a, R4b, R5a and R5b are not simultaneously hydrogen,

R6 is hydrogen, halogen or trifluoromethyl and

R7 is hydrogen or halogen,

and their salts.

An embodiment of the invention to be emphasized are compounds of the formula I\*



in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen,

one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy,  
one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy,  
where R4a, R4b, R5a and R5b are not simultaneously hydrogen,  
R6 is hydrogen, halogen or trifluoromethyl and  
R7 is hydrogen or halogen,  
and their salts.

An embodiment of the invention particularly to be emphasized are compounds of the formula I\*, in which


R1 is 1-4C-alkyl,  
R2 is 1-4C-alkyl or hydroxymethyl,  
R3 is hydrogen,  
R4a is hydrogen,  
R4b is hydroxyl or 1-4C-alkoxy,  
R5a is hydrogen, hydroxyl or 1-4C-alkoxy,  
R5b is hydrogen,  
R6 is hydrogen, halogen or trifluoromethyl and  
R7 is hydrogen or halogen,  
and their salts.

A preferred embodiment of the invention are compounds of the formula I\*, in which

R1 is 1-4C-alkyl,  
R2 is 1-4C-alkyl,  
R3 is hydrogen,  
R4a is hydrogen,  
R4b is hydroxyl,  
R5a is hydroxyl,  
R5b is hydrogen,  
R6 is hydrogen, halogen or trifluoromethyl and  
R7 is hydrogen or halogen,  
and their salts.

With the aid of the general formula I\*, the following exemplary compounds according to the invention may actually be mentioned by means of the substituent meanings and by the positions indicated for the substituents R3, R6 and R7 in the following Table 1 (Tab. 1):

Tab. 1



R1	R2	R3	R4a	R4b	R5a	R5b	R6	R7
CH <sub>3</sub>	CH <sub>3</sub>	H		O	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H		O	H	H	2-Cl	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	H	H	2-Cl	H
CH <sub>3</sub>	CH <sub>3</sub>	H		O	H	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	H	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OCH <sub>3</sub>	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OC <sub>2</sub> H <sub>5</sub>	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H		O	H	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	H	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>3</sub>	H		O	OH	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	6-Br		O	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	6-Br	H	OH	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	6-Cl	H	OH	H	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	6-Cl	H	OH	OH	H	H	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	2-Cl	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	4-Cl	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	2-NHCO-OCH <sub>3</sub>	6-CH <sub>3</sub>
CH <sub>3</sub>	CH <sub>3</sub>	H	H	OH	OH	H	2-NHCO-OC <sub>2</sub> H <sub>4</sub> -OCH <sub>3</sub>	6-CH <sub>3</sub>
CH <sub>3</sub>	CH <sub>2</sub> OH	H		O	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	H	H	H	H



Continuation of Tab. 1

R1	R2	R3	R4a	R4b	R5a	R5b	R6	R7
CH <sub>3</sub>	CH <sub>2</sub> OH	H		O	H	H	2-Cl	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	H	H	2-Cl	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H		O	H	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	H	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OCH <sub>3</sub>	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OC <sub>2</sub> H <sub>5</sub>	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H		O	H	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	H	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H		O	OH	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	6-Br		O	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	6-Br	H	OH	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	6-Cl	H	OH	H	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	6-Cl	H	OH	OH	H	H	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	2-Cl	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	2-Cl	6-Cl
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	4-Cl	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	2-CF <sub>3</sub>	H
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	2-NHCO-OCH <sub>3</sub>	6-CH <sub>3</sub>
CH <sub>3</sub>	CH <sub>2</sub> OH	H	H	OH	OH	H	2-NHCO-OC <sub>2</sub> H <sub>4</sub> -OCH <sub>3</sub>	6-CH <sub>3</sub>


and the salts of the compounds mentioned in Table 1, the character "O" (= oxygen) between R4a and R4b in Table 1 denoting a 7-oxo compound.

The compounds according to the invention can thus be prepared as described by way of example in the following examples, or using analogous process steps starting from appropriate starting compounds

The starting compounds are known or can be prepared analogously to the known compounds.

Depending on the substitution pattern in positions 7 and 8 (R4a/R4b or R5a/R5b), the compounds according to the invention can be prepared starting from N-protected 8-aminoimidazo[1,2-a]pyridines which are known or can be prepared in a known manner (see, for example, EP-A-0 299 470 or Kaminski et al., J. Med. Chem. 1985, 28, 876-892) according to the following reaction schemes:


Scheme 1:



The N-protected (Piv here and in the following schemes represents a customary protective group, preferably the pivaloyl group), 8-aminoimidazo[1,2-a]pyridine deprotonated in the 7-position is reacted with cinnamaldehyde. The addition product is initially oxidized (e.g. with manganese dioxide) and then epoxidized (e.g. with hydrogen peroxide). Under strongly basic and then strongly acidic conditions, the removal of the protective group and ring closure


takes place. The reduction of the keto group which, if desired, follows can be carried out, for example, using sodium borohydride.

Scheme 2:




Instead of the epoxidation according to Scheme 1, the protective group is removed and the ring is closed under strongly acidic conditions. The reduction to the alcohol which, if desired, follows is carried out by means of sodium borohydride.

Scheme 3:




The above scheme represents an example of an enantioselective synthesis, the same N-protected imidazo[1,2-a]pyridines being used as starting materials as in Scheme 1. The reaction of these imidazo[1,2-a]pyridines in deprotonated form with enantiomerically pure dioxolanes initially leads to a condensation product which can be cyclized under strongly acidic conditions with removal of the protecting groups. The subsequent reduction of the keto group using sodium borohydride (also see Scheme 1) leads in over 90% enantiomeric purity to the final product indicated.

Scheme 4:




Starting from the abovementioned 8-aminoimidazo[1,2-a]pyridines, the compounds substituted on the 8-amino group are obtained either by alkylation using suitable alkylating agents bearing substituents (e.g. R8a = hydrogen, R8b = halogen), or by reductive alkylations with appropriately substituted ketones [R8a and R8b together are O (oxygen)] with the aid of reductants such as sodium cyanoborohydride and these are ring-closed under base or acid catalysis to give the cyclic ketones, which for their part can be converted into the desired target compounds by suitable chemical transformations (see, for example, Schemes 1 and 2). If necessary, the group CO<sub>2</sub>R can also be initially reduced (aldehyde stage) before the cyclization, 7-hydroxy-substituted derivatives then being formed, which for their part can be converted into suitable target compounds by oxidation/reduction.

Scheme 5:



In a variant of the process outlined above in Scheme 4 where R5a and R8a = H (hydrogen) and R5b and R8b together = O (oxygen), the 8-aminoimidazo[1,2-a]pyridine is initially reacted with epoxycinnamic acid ester derivatives with regioselective epoxide opening (A). The products are cyclized under aprotic basic conditions (C). Alternatively to this, the mixture can be hydrolysed and the free carboxylic acid derivative cyclized under acidic conditions (D). In both cases, the keto group can then be reduced to the alcohol (G), as outlined in Scheme 1, for example using sodium borohydride. If the 8-aminoimidazo[1,2-a]pyridine is reacted with protected epoxycinnamaldehyde derivatives (B) the products can be ring-closed under acidic conditions after removal of the acetal protective group (F). A reduction of the ester function to the aldehyde and an acidic cyclization are likewise possible (E). Both the reduction of the keto function and the ring closure at the aldehyde stage can be carried out enantioselectively, such that when using the corresponding enantiomerically pure epoxy derivatives an enantioselective synthesis is possible.


Scheme 6:



In a further variant of Scheme 4, an enantioselective synthesis is outlined above. The dihydroxycinnamic acid derivative is activated in the benzylic position either directly or after introduction of a protective group on the second hydroxyl group. The products thus obtained are reacted with the 8-aminoimidazo[1,2-a]pyridine. Ring closure is then carried out, e.g. under basic conditions. The step (reduction) which, if desired, then follows is carried out analogously to Scheme 3.




Scheme 7:



8-Haloimidazo[1,2-a]pyridines (X = halogen) are reacted with suitably substituted β-phenyl-β-amino acids with heavy metal catalysis (Pd preferred) to give the substituted amines, which for their part are cyclized according to Scheme 4. Instead of the COOR group, the aldehyde group can also be used (as already mentioned in Scheme 4), if desired in the form of the acetal. Y is H (hydrogen) or a protective group which can be removed before or after ring closure.

Scheme 8:



Starting from the imidazole which is known or can be prepared in an analogous manner, the ring closure to be effected (optionally under protection of the hydroxy group) is favored by the presence of an enamine structure (equilibrium!). After the introduction of the double bond by oxidation, the reduction of the keto group to the alcohol can be carried out as outlined in Scheme 1.

In the above schemes, "R" is 1-4C-alkyl. In the ester groups mentioned by way of example (-COOR or -CO<sub>2</sub>R), there can be another leaving group instead of the radical -OR or there

can also be another group which can be used as far as its functionality is concerned instead of the ester group.

Compounds of the formula I in which R4a/R4b or R5a/R5b are 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or 1-4C-alkylcarbonyloxy can be prepared by customary derivatization measures, such as are familiar to the person skilled in the art (e.g. by alkylation or by acylation), from the corresponding compounds in which R4a/R4b or R5a/R5b are hydroxyl.

Compounds of the formula I in which R2 is hydroxy-1-4C-alkyl or the corresponding starting compounds of the Schemes 1 to 8 can be produced from the corresponding esters and aldehydes by reduction, for example with sodium borohydride or lithium aluminium hydride, in a customary manner (cf. WO 94/18199). If desired, the reduction for obtaining the hydroxy-1-4C-alkyl group can be accomplished simultaneously with the reduction of the keto group in position 8 and in particular in position 7 (R4a and R4b together are O).

The substances according to the invention are isolated and purified in a manner known per se, for example, by distilling off the solvent in vacuo and recrystallizing the residue obtained from a suitable solvent or subjecting it to one of the customary purification methods, such as, for example, column chromatography on suitable support material.

Salts are obtained by dissolving the free compound in a suitable solvent, e.g. in a chlorinated hydrocarbon, such as methyl chloride or chloroform, or a low molecular weight aliphatic alcohol (ethanol, isopropanol) which contains the desired acid, or to which the desired acid is subsequently added. The salts are obtained by filtering, reprecipitating, precipitating with a nonsolvent for the addition salt or by evaporating the solvent. Salts obtained can be converted by alkalization or by acidification into the free compounds, which in turn can be converted into salts. In this way, pharmacologically intolerable salts can be converted into pharmacologically tolerable salts.

The pure enantiomers, in particular the pure enantiomers of the formula I\*, to which the invention preferably relates, can be obtained in a manner familiar to the person skilled in the art, for example by enantioselective synthesis (see, for example, Scheme 3), by chromatographic separation on chiral separating columns, by derivatization with chiral auxiliary reagents, subsequent separation of diastereomers and removal of the chiral auxiliary group, by salt formation with chiral acids, subsequent separation of the salts and liberation of the desired compound from the salt, or by (fractional) crystallization from a suitable solvent.

The invention further relates to the processes and the process intermediates described in the above schemes, in particular those process intermediates of Schemes 1, 2, 3, 4, 5, 6 and 7, which can be isolated before the cyclization step.

The following examples serve to illustrate the invention further without restricting it. Likewise, further compounds of the formula I whose preparation is not described explicitly can be prepared analogously or in a manner familiar to the person skilled in the art using customary process techniques. The abbreviation min stands for minute(s), h for hour(s) and ee for enantiomeric excess.

### Examples

#### Final products

1. 2,3-Dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

A solution of 4.5 g of 2,3-dimethyl-7-(3-phenyl-1-oxo-2-propenyl)-8-pivaloyl-aminoimidazo[1,2-a]pyridine in 30 ml of dioxane is treated with 20 ml of conc. hydrochloric acid, refluxed for 8 h, adjusted to pH 7.0 with 2N sodium hydroxide solution with cooling and extracted three times with 50 ml of ethyl acetate. The combined extracts are washed with water, dried over potassium carbonate and concentrated to dryness in vacuo. The residual viscous oil is chromatographed on silica gel using ethyl acetate/petroleum ether (1:1) as an eluent. 2.6 g of the title compound of melting point 138-40°C are obtained.

2. 9-(2-Chlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

The title compound of melting point 80-2°C is obtained from 7-[3-(2-chlorophenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine in 73% yield analogously to Example 1.

3. 9-(2,6-Dichlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

The title compound of melting point 248-9°C is obtained from 7-[3-(2,6-dichlorophenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine in 41% yield analogously to Example 1.

4. 9-(2-Trifluoromethylphenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

The title compound of melting point 184-5°C is obtained from 7-[3-(2-trifluoromethylphenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine in 41% yield analogously to Example 1.

5. 7-Hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine

A suspension of 1 g of 2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one in 15 ml of methanol is treated at room temperature with 450 mg of sodium borohydride in small portions. The resulting yellowish solution is stirred for 2 h and then diluted with ice water. The precipitate which is deposited is filtered off with suction and washed with a little cold 2-propanol. 800 mg of the title compound of melting point 210-12°C are obtained.

6. 9-(2-Chlorophenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridine

The title compound of melting point 150-2°C is obtained from 9-(2-chlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one in 73% yield analogously to Example 5.

7. 9-(2,6-Dichlorophenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridine

The title compound of melting point 155-7°C is obtained from 9-(2,6-dichlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one in 72% yield analogously to Example 5.

8. 9-(2-Trifluoromethylphenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridine

The title compound of melting point 145-7°C is obtained from 9-(2-trifluoromethylphenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridin-7-one in 72% yield analogously to Example 5.

9. 8-Hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

A solution of 500 mg of 2,3-dimethyl-7-(2,3-epoxy-1-oxo-3-phenylpropyl)-8-pivaloyl-aminoimidazo[1,2-a]pyridine in 5 ml of dry ethanol is treated with vigorous stirring with 95 mg of lithium hydroxide and, after stirring at room temperature for 2 hours, cooled to 0°C in an ice bath. The crystals which are deposited are filtered off with suction and washed with a little cold ethanol. After drying in a high vacuum, the solid is introduced into 5 ml of 90% strength sulfuric acid at room temperature and stirred for 1 h. It is

then neutralized with 40% strength cooled sodium hydroxide solution with ice cooling. The precipitate which is deposited in this process is filtered off and dried in vacuo. 145 mg of the title compound of melting point 232-4°C are obtained.

10. 7,8-Dihydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine

700 mg of 8-hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridin-7-one are suspended in 15 ml of methanol and treated with 200 mg of sodium borohydride in portions at room temperature with stirring. After stirring for 2 hours, the mixture is poured onto 100 ml of ice water. The precipitate which is deposited is filtered off, briefly dried in vacuo and recrystallized from a little 2-propanol. 500 mg of the title compound of melting point 150-2°C are obtained.

11. (8R,9R)-2,3-Dimethyl-8-hydroxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one

10.8 g (24 mmol) of 2,3-dimethyl-7-[(2S,3R)-2,3-O-isopropylidene-3-phenylpropan-1-on-1-yl]-8-pivaloylaminoimidazo[1,2-a]pyridine (ee >95%, Daicel Chiralcel HPLC) are introduced into 50 ml of 70% strength sulfuric acid with ice cooling during the course of 4 min. A suspension is formed in the course of this, which turns into an orange solution after 30 min. After addition is complete, the ice bath is removed and the mixture is stirred on at room temperature. The reaction solution is added after 50 h to ice water and dichloromethane is added, then the mixture is adjusted to pH 8 using 6N sodium hydroxide solution and saturated sodium hydrogen-carbonate solution. The organic phase is separated off. The aqueous phase is extracted twice with dichloromethane. The organic phases are combined and washed with a little distilled water. The organic layer is then dried over anhydrous sodium sulfate, filtered and concentrated on a vacuum rotary evaporator. The concentrated residue is chromatographed on silica gel (eluent: dichloromethane/methanol 100/1). The main fraction is concentrated and treated with ethyl acetate, and the title compound crystallizes in the course of this as a yellow solid. This precipitate is filtered off with suction and dried to constant weight in a vacuum drying oven at 50°C. 4.22 g (57%, ee >95%, Daicel Chiralcel HPLC) of the title compound of melting point 231-4°C are obtained.

12. (7R,8R,9R)-2,3-Dimethyl-7,8-dihydroxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]-naphthyridine

6 g (19.52 mmol) of (8R,9R)-2,3-dimethyl-8-hydroxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one (ee >90%, Daicel Chiralcel HPLC) are suspended in 60 ml of methanol and cooled to -5° to 0°C in a methanol-ice bath. At this temperature, sodium borohydride (0.81 g, 21.47 mmol) is added by spatula during the course of 0.5 h (evolution of gas). After addition is complete, the mixture is stirred for a further 10 min, and then concentrated in a vacuum rotary evaporator at a bath temperature of 40°C. The oily residue obtained is taken up in distilled water and extracted three times with chloroform. The organic phases are combined and washed with a little water, then dried using anhydrous sodium sulfate and filtered. The filtrate is concentrated on a vacuum rotary evaporator and co-evaporated with acetone; the title compound crystallizes out in the course of this. The precipitate is filtered off, washed with acetone and dried to constant weight at 50°C in a vacuum drying oven. 5.15 g (85.3%, ee > 90%, Daicel Chiralcel HPLC) of the title compound are obtained as a colorless crystallizate of melting point 206-9°C.

13. (7S,8R,9R)-2,3-Dimethyl-7,8-dihydroxy-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7] naphthyridine

2 g of the mother liquor of example 12 are chromatographed on silica gel (eluent: ethyl acetate/methanol 19/1) to give 0.35 g of the title compound as an oil which crystallizes upon addition of ethyl acetate. Melting point.: 199-200°C (ethyl acetate).

14. (8R,9R)-3-Formyl-8-hydroxy-2-methyl-7-oxo-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine

(8R,9R)-8-hydroxy-2,3-dimethyl-7-oxo-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine (1 g) is dissolved in 20 ml of dried chloroform, and 5g of potassium permanganate was added. After stirring the reaction mixture at room temperature for 40 days, the solids are filtered off. The filtrate is chromatographed twice on silica gel (eluents: dichloromethane/methanol 13/1) to give 0.07 g of the title compound as a semisolid.



15. (7R,8R,9R)-3-Hydroxymethyl-7,8-dihydroxy-2-methyl-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine

0.07 g of (8R,9R)-3-formyl-8-hydroxy-2-methyl-7-oxo-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine are dissolved in 5 ml of dry methanol, and 0.1 g of sodium borohydride is added. The mixture is stirred for 30 min and concentrated in vacuo. The oily residue is partitioned between water and chloroform. The organic layer is separated, dried over anhydrous sodium sulfate and concentrated. The product is purified by flash chromatography on silica gel (eluent: dichloromethane/methanol 9/1) to give 0.05 g of the title compound as a semi solid.

<sup>1</sup>H-NMR (CD<sub>3</sub>OH, 400 MHz)  $\delta$  = 1.90 (s, 3H, 2-CH<sub>3</sub>), 3.87 (dd, J<sub>8,9</sub> = 9.5 Hz, J<sub>8,7</sub> = 8.0 Hz, 1H, 8-H), 4.45 (d, J<sub>9,8</sub> = 9.4 Hz, 1H, 9-H), 4.79 (bs, 2H, 3-CH<sub>2</sub>), 5.42 (d, J<sub>7,8</sub> = 8.0 Hz, 1H, 7-H), 7.03 (d, J<sub>6,5</sub> = 6.9 Hz, 1H, 6-H), 7.35 - 7.42 (m, 3H 9-Ph), 7.55 (d, J = 7.0 Hz, 2H, 9-Ph), 7.77 (d, J<sub>5,6</sub> = 7.0 Hz, 1H, 5-H).

16. (7S,8R,9R)-7,8-Isopropylidenedioxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydro-imidazo[1,2-h][1,7]naphthyridine

0.3 g of (7S,8R,9R)-2,3-dimethyl-7,8-dihydroxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine are dissolved in 5 ml of dry acetone and 10 ml of dry N,N-dimethyl formamide. 2,2-Dimethoxypropane (20 ml) and p-toluenesulfonic acid monohydrate (0.68 g) are added, and the mixture is stirred for 20 h at room temperature. The reaction mixture is partitioned between water and dichloromethane. The organic layer is separated, washed with water and dried over anhydrous sodium sulfate. After evaporation of the solvent, the residue is chromatographed on silica gel (eluent: ethyl acetate/methanol 20/1) to give 0.2 g of the title compound as colourless needles, melting point: 231-232°C (dec., diethyl ether).

## Starting compounds

### A. 2,3-Dimethyl-7-(3-phenyl-1-oxo-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine

#### Method A

#### a) 7-Tributylstannyl-2,3-dimethyl-8-pivaloylaminoimidazo[1,2-a]pyridine

A solution of 1 g of 2,3-dimethyl-8-pivaloylaminoimidazo[1,2-a]pyridine in 40 ml of diethyl ether is treated dropwise at -78°C with 8 ml of a 1.5 molar solution of t-butyllithium in n-pentane. The mixture is stirred for 15 min and then treated with 3.3 ml of tri-n-butyltin chloride. The internal temperature is then allowed to rise to room temperature, the mixture is poured onto ice water and extracted three times with ethyl acetate, the combined extracts are washed with a little water and dried over potassium carbonate, the solvent is stripped off in vacuo and the oil obtained is chromatographed on silica gel using ethyl acetate/petroleum ether (1:3) as an eluent. 1.3 g of 7-tributylstannyl-2,3-dimethyl-8-pivaloylaminoimidazo[1,2-a]pyridine are obtained as a viscous oil.

#### b) 2,3-Dimethyl-7-(3-phenyl-1-oxo-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine

A solution of 1 g of 7-tributylstannyl-2,3-dimethyl-8-pivaloylaminoimidazo[1,2-a]pyridine in 15 ml of tetrahydrofuran is treated successively with 85 mg of lithium chloride, 60 mg of bis(acetonitrile)palladium(II) chloride and 340 mg of cinnamoyl chloride. The mixture is stirred at 60°C for 3 h. The yellowish precipitate is filtered off with suction after cooling to 0°C and washed with a little tetrahydrofuran and diethyl ether. After drying in vacuo, 720 mg of the title compound are obtained as the hydrochloride salt of melting point 263-5°C (with decomposition).

#### Method B

#### a) 2,3-Dimethyl-7-(3-phenyl-1-hydroxy-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine

A vigorously stirred solution of 41 g of 8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine is treated dropwise at -78°C under argon protective gas with 320 ml of a commercially available, 1.5 molar solution of t-butyllithium in n-pentane such that the temperature does not exceed -70°C. After stirring at -78°C for a further 15 min, a solution of 61 g of cinnamaldehyde in 50 ml of dry diethyl ether is added dropwise

(internal temperature < -68°C). The mixture is then allowed to warm to room temperature, and is poured cautiously onto ice water and extracted three times with a total of 500 ml of ethyl acetate, the reddish-colored, organic phase is washed with distilled water and dried over sodium sulfate, and the solvent is stripped off in vacuo. The residual, yellowish suspension is treated with diethyl ether. The crystals obtained are filtered off with suction. 30 g of 2,3-dimethyl-7-(3-phenyl-1-hydroxy-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine of melting point 194-5°C are obtained.

b) 2,3-Dimethyl-7-(3-phenyl-1-oxo-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine

A solution of 35.5 g of 2,3-dimethyl-7-(3-phenyl-1-hydroxy-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine in 900 ml of trichloromethane is treated with 60 g of manganese dioxide and stirred vigorously at room temperature for 20 h. The mixture is then filtered, the filtrate is concentrated to dryness in vacuo and the oil obtained is treated with a little diisopropyl ether. The crystals obtained in this process are filtered off with suction. 31.5 g of the title compound of melting point 108-10°C are obtained.

B. 7-[3-(2-Chlorophenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine

The title compound of melting point 158-60°C is obtained in 42% yield as the hydrochloride analogously to Example A, method A, by corresponding reaction with 2-chlorocinnamoyl chloride.

C. 7-[3-(2,6-Dichlorophenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine

The title compound of melting point 218-19°C is obtained in 51% yield as the hydrochloride analogously to Example A, method A, by corresponding reaction with 2,6-dichlorocinnamoyl chloride.

D. 7-[3-(2-Trifluoromethylphenyl)-1-oxo-2-propenyl]-8-pivaloylamino-2,3-dimethylimidazo[1,2-a]pyridine

The title compound of melting point 206-8°C is obtained in 12% yield as the hydrochloride analogously to Example A, method A, by corresponding reaction with 2-trifluoromethylcinnamoyl chloride.

E. 2,3-Dimethyl-7-(2,3-epoxy-1-oxo-3-phenylpropyl)-8-pivaloylaminoimidazo[1,2-a]pyridine

A mixture of 4 g of 2,3-dimethyl-7-(3-phenyl-1-oxo-2-propenyl)-8-pivaloylaminoimidazo[1,2-a]pyridine in 60 ml of acetone and 400 mg of sodium hydroxide in 12 ml of water is treated dropwise with vigorous stirring at 30°C with 5.6 ml of commercially available, 30% strength aqueous hydrogen peroxide (20 min). After stirring at 30°C for a further 30 minutes, the mixture is cooled to 0°C and treated with a mixture of 60 ml of water, 13 g of sodium thiosulfate and 30 ml of ethyl acetate. After phase separation, the aqueous phase is extracted with 20 ml of ethyl acetate. The organic phases are combined, washed with a little water and dried over potassium carbonate. After stripping off the solvent in vacuo, the residual oil is dried in a high vacuum. 4 g of the title compound are obtained as an amorphous mass.

F. 2,3-Dimethyl-7-[(2S,3R)-2,3-O-isopropylidene-3-phenylpropan-1-on-1-yl]-8-pivaloylaminoimidazo[1,2-a]pyridine

60 g (0.245 mol) of 2,3-dimethyl-8-pivaloylaminoimidazo[1,2-a]pyridine are dissolved in 1.5 l of anhydrous diethyl ether with exclusion of moisture and under an argon atmosphere and cooled to -75°C. By means of a flex needle, 408 ml (0.612 mol) of tert-butyllithium solution (1.5 M in n-pentane) are added dropwise such that the temperature does not exceed -65°C (30 min). A red suspension is formed. After addition is complete, the suspension is stirred at -75°C for a further 30 min. 1/3 of a solution of 145 g of methyl (2S,3R)-2,3-O-isopropylidene-3-phenylpropionate (ee: 99.05%, Daicel Chiralcel HPLC) in 150 ml of absolute THF is then slowly added dropwise at a temperature of below -65°C during the course of 30 min. The residual quantity is then briskly added dropwise (5 min), a temperature rise to -60°C taking place. After addition is complete the cooling bath is removed. On reaching an internal temperature of -30°C, 20 ml of methanol are added and at an internal temperature of 0°C 200 ml of distilled water are added. The aqueous phase is separated off in a separating funnel, the organic phase is washed five times with 100 ml of distilled water each time, then the organic phase is extracted three times with 10% strength sulfuric acid (200 ml, 50 ml, 50 ml). The sulfuric acid phases are combined, treated with 200 ml of dichloromethane and adjusted to pH 2.3 with 10N sodium hydroxide solution and with ice cooling and vigorous stirring. The organic phase is separated off. The aqueous phase is extracted with 30 ml of dichloromethane. The combined dichloromethane phases are washed twice with a little distilled water. The organic phase is then dried over anhydrous sodium sulfate and the solvent is completely stripped off in vacuo. A brown oil is obtained which is treated with 50 ml of diethyl

- 27 -

ether. After seeding, crystals are formed which are filtered off after standing overnight and washed with diethyl ether. After drying in vacuo, 57.7 g (52.5%, ee > 99%, Daicel Chiralcel HPLC) of the title compound of melting point 76-80°C are obtained as a pale yellow powder.

### Commercial utility

The compounds of the formula I and their salts have useful pharmacological properties which make them commercially utilizable. In particular, they exhibit a marked inhibition of gastric acid secretion and an excellent gastric and intestinal protective action in warm-blooded animals, in particular humans. In this context, the compounds according to the invention are distinguished by a high selectivity of action, an advantageous duration of action, a particularly good enteral activity, the absence of significant side effects and a large therapeutic breadth.

"Gastric and intestinal protection" in this connection is understood as meaning the prevention and treatment of gastrointestinal diseases, in particular of gastrointestinal inflammatory diseases and lesions (such as, for example, stomach ulcers, duodenal ulcers, gastritis, hyperacidic or medicament-related functional gastropathy), which can be caused, for example, by microorganisms (e.g. *Helicobacter pylori*), bacterial toxins, medicaments (e.g. certain antiinflammatories and antirheumatics), chemicals (e.g. ethanol), gastric acid or stress situations.

In their excellent properties, the compounds according to the invention surprisingly prove to be clearly superior to the compounds known from the prior art in various models in which the antiulcerogenic and the antisecretory properties are determined. On account of these properties, the compounds of the formula I and their pharmacologically tolerable salts are outstandingly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of disorders of the stomach and/or intestine.

The invention therefore further relates to the compounds according to the invention for use in the treatment and/or prophylaxis of the abovementioned diseases.

The invention likewise comprises the use of the compounds according to the invention for the production of medicaments which are employed for the treatment and/or prophylaxis of the abovementioned diseases.

The invention furthermore comprises the use of the compounds according to the invention for the treatment and/or prophylaxis of the abovementioned diseases.

The invention furthermore relates to medicaments which contain one or more compounds of the formula I and/or their pharmacologically tolerable salts.

The medicaments are prepared by processes known per se, which are familiar to the person skilled in the art. As medicaments, the pharmacologically active compounds according to the

invention (= active compounds) are employed either as such, or preferably in combination with suitable pharmaceutical auxiliaries or excipients in the form of tablets, coated tablets, capsules, suppositories, patches (e.g. as TTS), emulsions, suspensions or solutions, where the active compound content is advantageously between 0.1 and 95% and where, by the appropriate choice of the auxiliaries and excipients, a pharmaceutical administration form (e.g. a delayed-release form or an enteric form) exactly suited to the active compound and/or to the desired onset of action can be achieved.

The person skilled in the art is familiar, on the basis of his expert knowledge, with auxiliaries or excipients which are suitable for the desired pharmaceutical formulations. Beside solvents, gel-forming agents, suppository bases, tablet auxiliaries and other active compound carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, flavor corrigents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complexing agents (e.g. cyclodextrins).

The active compounds can be administered orally, parenterally or percutaneously.

In general, it has proven advantageous in human medicine to administer the active compound(s) in the case of oral administration in a daily dose from approximately 0.01 to approximately 20, preferably 0.05 to 5, in particular 0.1 to 1.5, mg/kg of body weight, if appropriate in the form of several, preferably 1 to 4, individual doses to achieve the desired result. In the case of parenteral treatment, similar or (in particular in the case of intravenous administration of the active compounds), as a rule, lower doses can be used. The optimal dose and manner of administration of the active compounds necessary in each case can easily be determined by any person skilled in the art on the basis of his expert knowledge.

If the compounds according to the invention and/or their salts are to be employed for the treatment of the abovementioned diseases, the pharmaceutical preparations can also contain one or more pharmacologically active constituents of other pharmaceutical groups. Examples which may be mentioned are: tranquilizers (for example from the benzodiazapines group, e.g. diazepam), spasmolytics (e.g. bietamiverine or camylofin), anticholinergics (e.g. oxyphencyclimine or phencarbamide), local anesthetics (e.g. tetracaine or procaine), and, if appropriate, also enzymes, vitamins or amino acids.

To be emphasized in this connection, in particular, is the combination of the compounds according to the invention with pharmaceuticals which inhibit acid secretion, such as, for example, H<sub>2</sub> blockers (e.g. cimetidine, ranitidine), H<sup>+</sup>/K<sup>+</sup> - ATPase inhibitors (e.g. omeprazole, pantoprazole), or furthermore with so-called peripheral anticholinergics (e.g. pirenzepine, telenzepine), and with gastrin antagonists with the aim of increasing the main

action in an additive or superadditive sense and/or of eliminating or decreasing the side effects, or furthermore the combination with antibacterially active substances (e.g. cephalosporins, tetracyclines, penicillins, macrolides, nitroimidazoles or alternatively bismuth salts) for the control of *Helicobacter pylori*. Antibacterially active combination components which may be mentioned are, for example, mezlocillin, ampicillin, amoxycillin, cefalothin, cefoxitin, cefotaxime, imipenem, gentamycin, amikacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e.g. clarithromycin + metronidazole).



### Pharmacology

The excellent gastric protective action and the gastric acid secretion-inhibiting action of the compounds according to the invention can be demonstrated in animal experimental models. The compounds according to the invention investigated in the model mentioned below have been provided with numbers which correspond to the numbers of these compounds in the examples.

#### Testing of the secretion-inhibiting action on the perfused rat stomach

Table A below shows the effects of the compounds according to the invention on the pentagastrin-stimulated acid secretion of the perfused rat stomach in vivo after intravenous administration.

**Table A**

No.	Dose ( $\mu\text{mol/kg}$ ) i.v.	Inhibition of acid secretion (%)
5	3	100
6	3	100
10	3	100
12	3	100
13	3	100

#### Methodology

The abdomen of anesthetized rats (CD rat, female, 200-250 g; 1.5 g/kg i.m. urethane) was opened after tracheotomy by means of a median upper abdominal incision and a PVC catheter was fixed transorally in the esophagus and another via the pylorus such that the ends of the tube just projected into the gastric lumen. The catheter leading from the pylorus led outwards into the right abdominal wall through a side opening.


After thorough rinsing (about 50-100 ml), warm physiological NaCl solution at 37°C was continuously passed through the stomach (0.5 ml/min, pH 6.8-6.9; Braun-Unita I). The pH (pH meter 632, glass electrode EA 147;  $\phi$  = 5 mm, Metrohm) and, by titration with a freshly prepared 0.01 N NaOH solution to pH 7 (Dosimat 665 Metrohm), the secreted HCl were determined in the effluent in each case collected at an interval of 15 minutes.

The gastric secretion was stimulated by continuous infusion of 1  $\mu\text{g/kg}$  (= 1.65 ml/h) of i.v. pentagastrin (left femoral vein) about 30 min after the end of the operation (i.e. after determination of 2 preliminary fractions). The substances to be tested were administered intravenously in 1 ml/kg liquid volumes 60 min after the start of the pentagastrin continuous infusion.

The body temperature of the animals was kept at a constant 37.8-38°C by infrared irradiation and heat pads (automatic, stepless control by means of a rectal temperature sensor).

Patent Claims

1. A compound of the formula I



in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen or halogen,

one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or 1-4C-alkylcarbonyloxy, or in which R4a and R4b together are O (oxygen),

one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl, 1-4C-alkoxy, 1-4C-alkoxy-1-4C-alkoxy or 1-4C-alkylcarbonyloxy, or in which R5a and R5b together are O (oxygen),

or in which

one of the substituents R4a and R4b on the one hand and one of the substituents R5a and R5b on the other hand is in each case hydrogen, and the other substituents in each case together form a methylenedioxy radical (-O-CH<sub>2</sub>-O-) or an ethylenedioxy radical (-O-CH<sub>2</sub>-CH<sub>2</sub>-O-),

where R4a, R4b, R5a and R5b are not simultaneously hydrogen,

R6 is hydrogen, halogen, 1-4C-alkyl, 1-4C-alkoxy, 1-4C-alkoxycarbonylamino, 1-4C-alkoxy-1-4C-alkoxycarbonylamino or trifluoromethyl and

R7 is hydrogen, halogen, 1-4C-alkyl or 1-4C-alkoxy,

or its salts.

2. The compound of the formula I as claimed in claim 1, in which


R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen,

one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy, or in which R4a and R4b together are O (oxygen),  
 one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy, or in which R5a and R5b together are O (oxygen),  
 where R4a, R4b, R5a and R5b are not simultaneously hydrogen,  
 R6 is hydrogen, halogen or trifluoromethyl and  
 R7 is hydrogen or halogen  
 or its salts.

3. The compound as claimed in claim 1, which has the formula I\*



in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxy-1-4C-alkyl,

R3 is hydrogen,

one of the substituents R4a and R4b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy,

one of the substituents R5a and R5b is hydrogen and the other is hydrogen, hydroxyl or 1-4C-alkoxy,

where R4a, R4b, R5a and R5b are not simultaneously hydrogen,

R6 is hydrogen, halogen or trifluoromethyl and

R7 is hydrogen or halogen,

or its salts.

4. The compound of the formula I\* as claimed in claim 3,

in which

R1 is 1-4C-alkyl,

R2 is 1-4C-alkyl or hydroxymethyl,

R3 is hydrogen,

R4a is hydrogen,

R4b is hydroxyl or 1-4C-alkoxy,  
R5a is hydrogen, hydroxyl or 1-4C-alkoxy,  
R5b is hydrogen,  
R6 is hydrogen, halogen or trifluoromethyl and  
R7 is hydrogen or halogen,  
or its salts.

5. The compound of the formula I\* as claimed in claim 3, in which

R1 is 1-4C-alkyl,  
R2 is 1-4C-alkyl,  
R3 is hydrogen,  
R4a is hydrogen,  
R4b is hydroxyl,  
R5a is hydroxyl,  
R5b is hydrogen,  
R6 is hydrogen, halogen or trifluoromethyl and  
R7 is hydrogen or halogen,  
and its salts.

6. The compound as claimed in claim 1, selected from the group consisting of  
7,8-dihydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one,  
9-(2-chlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one,  
9-(2,6-dichlorophenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one,  
9-(2-trifluoromethylphenyl)-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one,  
7-hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
9-(2-chlorophenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
9-(2,6-dichlorophenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
9-(2-trifluoromethylphenyl)-7-hydroxy-2,3-dimethyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
8-hydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-7-one,  
(7S,8R,9R)-2,3-Dimethyl-7,8-dihydroxy-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
(8R,9R)-3-Formyl-8-hydroxy-2-methyl-7-oxo-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,

(7R,8R,9R)-3-Hydroxymethyl-7,8-dihydroxy-2-methyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine and  
(7S,8R,9R)-7,8-Isopropylidenedioxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine,  
or a salt thereof.

7. The compound as claimed in claim 6 with 9R-configuration, or a salt thereof.
8. The compound as claimed in claim 1 having the chemical name (7R,8R,9R)-7,8-dihydroxy-2,3-dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridine, or a salt thereof.
9. A medicament comprising a compound as claimed in claim 1 and/or a pharmacologically tolerable salt thereof together with customary pharmaceutical auxiliaries and/or excipients.
10. The use of compounds as claimed in claim 1 and their pharmacologically tolerable salts for the production of medicaments for the prevention and treatment of gastrointestinal diseases.

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/14 A61K31/435 //(C07D471/14,235:00,221:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 468 400 A (GOLD ET AL.) 28 August 1984 cited in the application see claims 1,12-17	1,9,10
A	WO 94 18199 A (BYK GULDEN-LOMBERG) 18 August 1994 see claims 1,8	1,10



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

31 August 1998

Date of mailing of the international search report

07/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4468400	A	28-08-1984	NONE	
WO 9418199	A	18-08-1994	AU 678434 B	29-05-1997
			AU 6039194 A	29-08-1994
			BG 99855 A	30-04-1996
			CA 2156078 A	18-08-1994
			CN 1119863 A	03-04-1996
			CZ 9502088 A	13-12-1995
			EP 0683780 A	29-11-1995
			FI 953838 A	06-09-1995
			HU 72436 A	29-04-1996
			IL 108520 A	30-09-1997
			JP 8506333 T	09-07-1996
			NO 953187 A	14-08-1995
			NZ 261579 A	24-03-1997
			PL 310171 A	27-11-1995
			SK 99795 A	06-12-1995
			US 5665730 A	09-09-1997
			ZA 9400990 A	17-08-1994